| dc.contributor.author |
Malande, Oliver Ombeva |
|
| dc.contributor.author |
Musyoki, Andrew Munyalo |
|
| dc.contributor.author |
Adamu, Victor Eneojo |
|
| dc.contributor.author |
Mun- ube, Deogratias |
|
| dc.contributor.author |
Hokororo, Adolfine |
|
| dc.contributor.author |
Sabahelzain, Majdi |
|
| dc.contributor.author |
Nzoka, Mutunga |
|
| dc.contributor.author |
Afaayo, Rachel Nakatugga |
|
| dc.contributor.author |
Chege, Christine Karanja |
|
| dc.contributor.author |
Omayo, Leonidah Nyamusi |
|
| dc.contributor.author |
Nkwinika, Var- setile Varster |
|
| dc.date.accessioned |
2026-07-21T06:25:15Z |
|
| dc.date.available |
2026-07-21T06:25:15Z |
|
| dc.date.issued |
2021-10 |
|
| dc.identifier.uri |
file:///home/systems/Downloads/COVID-19Vaccinesmythsandmisconception.pdf |
|
| dc.identifier.uri |
http://ir.mu.ac.ke:8080/jspui/handle/123456789/10380 |
|
| dc.description.abstract |
Coronavirus disease (COVID-19) is an infectious disease
caused by the SARS-CoV-2 virus. At the start of the
pandemic, scientists and pharmaceutical companies
frantically searched for an effective vaccine. 1-4 Various
platforms have employed traditional vaccine develop-
ment approaches like live attenuated virus, inactivated
virus, recombinant-protein based, viral-like particles
and explored newer platforms like non-replicating viral
vector, replicating viral vector, peptide-based, DNA
and RNA based vaccines.1-8 There are currently over
300 COVID-19 candidate vaccines at different levels of
development but about ten are currently being used. |
en_US |
| dc.language.iso |
en |
en_US |
| dc.publisher |
Africa health |
en_US |
| dc.subject |
Vaccines |
en_US |
| dc.subject |
Myths |
en_US |
| dc.subject |
Misconceptions |
en_US |
| dc.subject |
COVID-19 |
en_US |
| dc.title |
COVID-19: Vaccines, myths, and misconceptions in Africa Experts share their insights |
en_US |
| dc.type |
Article |
en_US |